Cargando…

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatti, Milo, Andreoni, Massimo, Pea, Federico, Viale, Pierluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349200/ https://www.ncbi.nlm.nih.gov/pubmed/34376971 http://dx.doi.org/10.2147/DDDT.S313756

Ejemplares similares

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections
por: Barone, Rossella, et al.
Publicado: (2023)

An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients
por: Gatti, Milo, et al.
Publicado: (2021)

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients
por: Gatti, Milo, et al.
Publicado: (2021)

Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence
por: Gatti, Milo, et al.
Publicado: (2023)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia
por: Gatti, Milo, et al.
Publicado: (2022)

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
por: Gatti, Milo, et al.
Publicado: (2023)

Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring
por: Barone, Rossella, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis
por: Gatti, Milo, et al.
Publicado: (2023)

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
por: Gallerani, Altea, et al.
Publicado: (2023)

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring
por: Barone, Rossella, et al.
Publicado: (2023)

A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis
por: Gatti, Milo, et al.
Publicado: (2022)

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
por: Cojutti, Pier Giorgio, et al.
Publicado: (2022)

Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases
por: Gatti, Milo, et al.
Publicado: (2022)

Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics
por: Gatti, Milo, et al.
Publicado: (2021)

The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug–Disease Interaction Under Different Clinical Conditions
por: Gatti, Milo, et al.
Publicado: (2022)

Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter?
por: Pea, Federico, et al.
Publicado: (2009)

Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections
por: Gatti, Milo, et al.
Publicado: (2023)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
por: Sanz Codina, Maria, et al.
Publicado: (2022)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings
por: Gatti, Milo, et al.
Publicado: (2021)

Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
por: Gatti, Milo, et al.
Publicado: (2021)

Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta‐analysis
por: Gatti, Milo, et al.
Publicado: (2021)

Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies
por: Gatti, Milo, et al.
Publicado: (2021)

613. Clinical Outcomes Following Dalbavancin Administration during Outpatient Parenteral Antimicrobial Therapy
por: Tuan, Jessica, et al.
Publicado: (2021)

Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
por: Tuan, Jessica J., et al.
Publicado: (2022)

Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
por: Erviti, Juan, et al.
Publicado: (2017)

Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients
por: Gatti, Milo, et al.
Publicado: (2022)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context
por: De Nicolò, Amedeo, et al.
Publicado: (2021)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
por: Bork, Jacqueline T., et al.
Publicado: (2019)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

The FDA-Approved Essure Device Counseling Order Fails to Promote Patient Empowerment
por: Gunn, Christine M., et al.
Publicado: (2019)

Unmet definitions in thromboprophylaxis for hospitalized medical patients: An appraisal for the need of recommendation
por: Ávila Ferreira, Bruno, et al.
Publicado: (2022)

Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
por: Raschi, Emanuel, et al.
Publicado: (2022)

Beyond will: the empowerment conditions needed to abandon female genital mutilation in Conakry (Guinea), a focused ethnography
por: Doucet, Marie-Hélène, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bbv8a7dh77mk5822mpqomabbb6